LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
Triple negative breast cancer (TNBC) is a subtype of breast cancer with significant malignancy and poor prognosis but effective treatments are limited. Given the critical role of CDK4/6 in cell cycle and the apparent success of CDK4/6 inhibitors against certain cancer, this study attempted to utiliz...
Main Authors: | Jiahao Qiu, Xinfa Bai, Wenjing Zhang, Mingxu Ma, Wenyan Wang, Ye Liang, Hongbo Wang, Jingwei Tian, Pengfei Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.853993/full |
Similar Items
-
Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1
by: So Ra Choi, et al.
Published: (2021-06-01) -
Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
by: Zhaofeng Liu, et al.
Published: (2024-02-01) -
The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01) -
Method of Monitoring 26S Proteasome in Cells Revealed the Crucial Role of PSMA3 C-Terminus in 26S Integrity
by: Shirel Steinberger, et al.
Published: (2023-06-01) -
WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6
by: Jing Ji, et al.
Published: (2023-01-01)